Determining the efficacy and safety of anti-cirrhotic drugs for cholestatic liver disease remains a challenge because there are different modalities available to assess liver fibrosis in patients.

The complications of primary sclerosing cholangitis are very dangerous, they affect the digestive organs and other organs in the body. Therefore, early diagnosis is necessary for early treatment.